POTENTIAL REVERSAL OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY WITH TTR SPECIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY

In the majority of patients with ATTR cardiomyopathy death is due to progressive cardiac failure from restrictive cardiomyopathy. Since TTR is synthesized primarily by the liver reducing hepatic production of TTR, the substrate for amyloid fibril formation, is a logical way to inhibit progression of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A660-A660
Main Authors: Dasgupta, Noel Rakhi, Benson, Merrill D.
Format: Article
Language:English
Subjects:
Amyloid
Antisense oligonucleotides
Cardiology
Cardiomyopathy
Transthyretin
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the majority of patients with ATTR cardiomyopathy death is due to progressive cardiac failure from restrictive cardiomyopathy. Since TTR is synthesized primarily by the liver reducing hepatic production of TTR, the substrate for amyloid fibril formation, is a logical way to inhibit progression of ATTR. Conclusion Treatment to decrease availability of amyloid fibril substrate has been an effective treatment for AL (Ig light chain) and AA (reactive) amyloidosis.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)31201-4